• Akari Therapeutics named Vatnak Vat-Ho chief business officer to lead corporate strategy, partnering, licensing, investor engagement.
• Vat-Ho brings 20+ years in oncology business development, biopharma strategy, equity research, healthcare investing; worked on deals totaling $25 billion.
• Most recently served as chief business officer at Ryvu Therapeutics, where he closed an ADC payload collaboration with Exelixis.
• At Ryvu, he also originated a multi-target immuno-oncology research collaboration with BioNTech.
• Appointment comes as Akari advances TROP2-targeted ADC AKTX-101 toward the clinic, alongside its PH1 payload platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610130901PRIMZONEFULLFEED9844277) on October 13, 2026, and is solely responsible for the information contained therein.